Prostate-specific antigen

Seminars in Surgical Oncology

Volumn 18, Issue 1, 2000, Pages 3-9

  Brawer, Michael K ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

Age factors; Alpha 1 antichymotripsin; Carcinoma; Diagnosis; Predictive value of tests; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms; Sensitivity and specificity

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; DEVICE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REFERENCE VALUE; REVIEW;

ADULT; AGED; DECISION MAKING; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033986306     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200001/02)18:1<3::AID-SSU2>3.0.CO;2-I     Document Type: Review

References (58)

1. Mettlin CJ, Murphy GP: Why is the prostate cancer death rate declining in the United States?[editorial][published erratum appears in Cancer 1998;82:1802]. Cancer 1997;82:249-251.
2. Ferro MA, Barnes I, Roberts JB, Smith PJ: Tumor markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987;60:69-73.
3. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
4. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270: 860-864.
5. Cooner WH, Eggers CW, Lichtenstein P: Prostate cancer: new hope for early diagnosis. Ala Med 1987;56:13-16.
6. Brawer MK, Lange PH: Prostate-specific antigen in the screening, staging and follow up of early-stage prostate cancer: a review of recent developments. World J Urol 1989;7:7-11.
7. Brawer MK, Rennels MA, Nagle RB, et al: Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Path 1989;92:760-764.
8. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991;325:1324]. N Engl J Med 1991;324:1156-1161.
9. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate-specific antigen. J Urol 1992;147(3 Pt 2):841-845.
10. Dalton DL: Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989;33:465.
11. Neal DE Jr, Clejan S, Sarma D, Moon TD: PSA and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1002;20:105-111.
12. Armitage TG, Cooper EH, Newling DW, et al: The value of the measurement of serum prostate-specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 1988;62:584-589.
13. Yuan JJ, Coplen DE, Petros JA, et al: Effects of rectal examination, prostatic massage, ultrasonography, and needle biopsy on serum prostate-specific antigen levels. J Urol 1992;147(3 Pt 2):810-814.
14. Brawer MK, Schifman RB, Ahmann FR, et al: The effect of digital rectal examination on serum levels of prostate-specific antigen. Arch Path Lab Med 1988;112:1110-1112.
15. Oesterling JE, Bergstralh EJ: PSA following prostate biopsy and TURP: length of time necessary to achieve a stable value [Abstract]. J Urol 1991;145:251A.
16. Tchetgen MB, Song JT, Strawderman M, et al: Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996;47:511-516.
17. Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147(3 Pt 2):815-816.
18. Babaian RJ, Fritsche HA, Evans RB: Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990;4:135-137.
19. Benson MC, Whang IS, Olsson CA, et al: The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992;147(3 Pt 2):817-821.
20. Seaman E, Whang M, Olsson CA, et al: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-663.
21. Bazinet M, Meshref AW, Trudel C, et al: Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-52.
22. Rommel FM, Augusta VE, Breslin JA, et al: The use of prostate-specific antigen and prostate-specific antigen density in the diagnosis of prostate cancer in a community based urology practice [published erratum appears in J Urol 1994;152(2 Pt 1):495]. J Urol 1994;151:88-93.
23. Littrup PJ, Kane RA, Mettlin CJ, et al: Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Cancer 1994;74: 3146-3158.
24. Bangma CH, Kranse R, Blijenberg BG, Schroder FH: The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology 1995;46:773-778.
25. Brawer MK, Aramburu EA, Chen GL, et al: The inability of prostate-specific antigen density index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993;150(2 Pt 1):369-373.
26. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate-specific antigen level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994;74: 1615-1620.
27. Ohori M, Dunn JK, Scardino PT: Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995;46:666-671.
28. Wener MH, Daum PR, Brawer MK: Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995;41(12 Pt 1):1730-1737.
29. Stamey TA: Making the most out of six systematic sextant biopsies [Review]. Urology 1995;45:2-11.
30. Brawer MK: How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 1995;45:148-164.
31. Letran JL, Meyer GE, Loberiza FR, Brawer MK: The effect of prostate volume on the yield of needle biopsy. J Urol 1998;160:1718-1721.
32. Zlotta AR, Djavan B, Marberger M, Schulman CC: Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997;157:1315-1321.
33. Maeda H, Ishitoya S, Maekawa S, et al: Prostate specific antigen density of the transition zone in the detection of prostate cancer [Abstract]. J Urol 1997;158:58A.
34. Lin DW, Gold MH, Ransom S, et al: Transition zone prostate specific antigen density: lack of utility in prediction of prostatic carcinoma. J Urol 1998;160:77-82.
35. Carter HB, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-3328.
36. Brawer MK, Beatie J, Wener MH, et al: Screening for prostatic carcinoma with prostate-specific antigen: results of the second year. J Urol 1993;150:106-109.
37. Porter JR, Hayward R, Brawer MK: The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy [Abstract]. J Urol 1994;151:293A.
38. Catalona WJ, Smith DS, Ratliff TL: Value or measurement of the rate of change of serum PSA levels in prostate cancer screening [Abstract]. J Urol 1993;150:300A.
39. Carter HB, Pearson JD, Waclawiw Z, et al: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45: 591-596.
40. Nixon RG, Wener MH, Smith KM, et al: Day-to-day changes in free and total PSA: significance of biological variation. PCPD 1998;1:90-96.
41. Nixon RG, Wener MH, Smith KM, et al: Biological variation of prostate-specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients [Review]. J Urol 1997;157:2183-2190.
42. Oesterling JE, Cooner WH, Jacobsen SJ, et al: Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 1993;20:671-680.
43. Reissigl A, Pointner J, Horninger W, et al: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening population. Urology 1995; 46:662-665.
44. Borer JG, Serman J, Solomon MC, et al: Age-specific reference ranges for prostate-specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures [Abstract]. J Urol 1996;155:48A.
45. Etzioni R, Shen Y, Petteway JC, Brawer MK: Age-specific prostate-specific antigen: a reassessment. Prostate Suppl 1996;7: 70-77.
46. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-763.
47. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and a 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
48. Christensson A, Bjork T, Nilsson O, et al: Serum prostate-specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:105.
49. Luderer AA, Chen YT, Soriano TF, et al: Measurement of the proportion of free-to-total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-194.
50. Higashihara E, Nutahara K, Kojima M, et al: Significance of serum free prostate specific antigen in the screening of prostate cancer [Review]. J Urol 1996;156:1964-1968.
51. Chen YT, Luderer AA, Thiel RP, et al: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-524.
52. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-1547.
53. Woodrum DL, Brawer MK, Partin AW, et al: Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer [Review]. J Urol 1998;159:5-12.
54. Roth HJ, Christensen-Stewart S, Brawer MK: A comparison of three free and total PSA assays. PCPD 1998;1:326-331.
55. Nixon RG, Meyer GE, Blase AB, et al: Comparison of 3 investigational assays for the free form of prostate-specific antigen. J Urol 1998;160:420-425.
56. Letran JL, Blase AB, Loberiza FR, et al: Repeat ultrasound-guided prostate needle biopsy: use of free-to-total PSA ratio in predicting prostatic carcinoma. J Urol 1998;160:426-429.
57. Brawer MK, Meyer GE, Letran JL, et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-378.
58. Brawer MK, Partin AW: The promise of new serum markers in prostate cancer. Contemp Urol 1999;11:45-46,49-50,55-56,58,61-62,64,69-70,75.